epidemiologyЭпидемиология и ВакцинопрофилактикаEpidemiology and Vaccinal Prevention2073-30462619-0494«Numicom» LLC10.31631/2073-3046-2022-21-3-90-95epidemiology-1563Research ArticleОБЗОРREVIEWРаспространённость в мире гепатита DThe prevalence of viral hepatitis D in the worldhttps://orcid.org/0000-0003-4228-9044АкимкинВ. Г.AkimkinV. G.

Василий Геннадьевич Акимкин  – академик РАН, д. м. н., профессор, директор

111123, Москва, ул. Новогиреевская, 3а

+7  (903) 013-09-74

Vasily G. Akimkin – Academician of the Russian Academy of Sciences, Dr. Sci. (Med.), Professor, Director Central Research Institute of Epidemiology

3a, ul. Novogireevskaya, Moscow, 111123

+7 (903) 013-09-74

vgakimkin@yandex.ruhttps://orcid.org/0000-0002-6539-4878ПонежеваЖ. Б.PonezhevaZ. B.

Жанна Бетовна Понежева – д. м. н., заведующая клиническим отделом инфекционной патологии

111123, Москва, ул. Новогиреевская, 3а

+7 (903) 145-50-07

Zhanna B. Ponezheva  – Dr. Sci. (Med.), Head of the clinical department of infectious pathology

3a, ul. Novogireevskaya, Moscow, 111123

+7  (903) 145-50-07

doktorim@mail.ruhttps://orcid.org/0000-0002-9682-2230ОмароваХ. Г.OmarovaKh. G.

Хадижат Гаджиевна Омарова  – к. м. н., старший научный сотрудник клинического отдела инфекционной патологии

111123, Москва, ул. Новогиреевская, 3а

+7  (926) 286-42-66

Khadizhat G. Omarova – Cand. Sci. (Med.), Senior researcher of the Central Research Institute of Epidemiology

3a, ul. Novogireevskaya, Moscow, 111123

+7 (926) 286-42-66

omarova71@inbox.ruhttps://orcid.org/0000-0003-4483-5993ГоловероваЮ. А.GoloverovaYu. А.

Юлия Александровна Головерова  – лаборант-исследователь лаборатории инфекций, связанных с оказанием медицинской помощи

111123, Москва, ул. Новогиреевская, 3а

+7  (901) 332-46-57

Yuliya A. Goloverova – laboratory-researcher laboratory of healthcare-associated infections Central Research Institute of Epidemiology

3a, ul. Novogireevskaya, Moscow, 111123

+7 (901) 332-46-57

yuliya_goloverova@mail.ruhttps://orcid.org/0000-0002-1322-0155УглеваС. В.UglevaS. V.

Светлана Викторовна Углева  – д. м. н., доцент, консультант организационно-методического отдела административно-управленческого подразделения

111123, Москва, ул. Новогиреевская, 3а

+7 (905) 360-87-77

Svetlana V. Ugleva – Dr. Sci. (Med.), Assoc. Prof., consultant, Organizational and methodological department, Administrative division, Central Research Institute of  Epidemiology

3a, ul. Novogireevskaya, Moscow, 111123

+7 (905) 360-87-77

uglevas@bk.ruhttps://orcid.org/0000-0003-4930-5756ШабалинаС. В.ShabalinaS. V.

Светлана Васильевна Шабалина  – д. м. н., профессор, ведущий научный сотрудник клинического отдела инфекционной патологии

111123, Москва, ул. Новогиреевская, 3а

+7 (906) 743-48-64

Svetlana V. Shabalina – Dr. Sci. (Med.), Professor, Leading researcher clinical department of infectious pathology Central Research Institute of Epidemiology

3a, ul. Novogireevskaya, Moscow, 111123

+7  (906) 743-48-64

svs2810@mail.ruФБУН Центральный НИИ Эпидемиологии РоспотребнадзораРоссияCentral Research Institute of Epidemiology, Federal Service on Customers Rights Protection Human Well-being SurveillanceRussian Federation2022100720222139095Copyright © Акимкин В.Г., Понежева Ж.Б., Омарова Х.Г., Головерова Ю.А., Углева С.В., Шабалина С.В., 20222022Акимкин В.Г., Понежева Ж.Б., Омарова Х.Г., Головерова Ю.А., Углева С.В., Шабалина С.В.Akimkin V.G., Ponezheva Z.B., Omarova K.G., Goloverova Y.А., Ugleva S.V., Shabalina S.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.epidemvac.ru/jour/article/view/1563

Актуальность. По мнению многих исследователей, гепатит D в 80–90% случаев ухудшает прогноз течения гепатита В, ускоряя фиброз и приводя к циррозу печени или к гепатоцеллюлярной карциноме. Цель. Представить обзор данных о распространённости гепатита D в Российской Федерации и за рубежом. Выводы. Гепатит D наиболее распространен в таких регионах мира, как Африка, Южная Америка, Ближний Восток, Северная Азия и в некоторых странах Средиземноморья. Среди уязвимых групп населения большая роль принадлежит лицам, употребляющим инъекционные наркотики. Положительную роль в профилактике распространения гепатита D играет вакцинация против гепатита В.

Relevance According to many researchers, hepatitis D worsens the prognosis of hepatitis B in 80–90% of cases, accelerating fibrosis and leading to liver cirrhosis or hepatocellular carcinoma. Aims. To present a review of data on prevalence of hepatitis D in the Russian Federation and abroad. Conclusions. Hepatitis D is most common in such regions of the world as: Africa, South America, Middle East, North Asia and in some Mediterranean countries. Conclusions. Injecting drug users play a large role among vulnerable populations. Hepatitis B vaccination limits the spread of hepatitis D.

гепатит Dгепатит ВHBsAgкоинфекциясуперинфекцияцирроз печенигепатоцеллюлярная карциномаviral hepatitis Dviral hepatitis BHBsAgcoinfectionsuperinfectionliver cirrhosishepatocellular carcinomaReferencesLerut J.P., Donataccio M., Ciccarelli O., et al. Liver transplantation and HBsAg-positive postnecrotic cirrhosis: adequate immunoprophylaxis and delta virus co-infection as the significant determinants of long-term prognosis J Hepatol. 1999. Vol. 30, № 4. P. 706–714. doi: 10.1016/s0168-8278(99)80203-7Lerut J.P., Donataccio M., Ciccarelli O., et al. Liver transplantation and HBsAg-positive postnecrotic cirrhosis: adequate immunoprophylaxis and delta virus co-infection as the significant determinants of long-term prognosis. J Hepatol. 1999. Vol. 30, № 4. P. 706–714. doi: 10.1016/s0168-8278(99)80203-7Исаева О. В., Кюрегян К. К. Вирусный гепатит дельта: недооцененная угроза Инфекционные болезни: новости, мнения, обучение. 2019. Т. 8, № 2. С. 72–79. doi: 10.24411/2305-3496-2019-12010Isaeva O.V., Kuregyan K.K. Viral hepatitis delta: an underestimated threat. Infektsionnye bolezni: novosti, mneniya, obuchenie. Infectious Diseases: News, Opinions, Training. 2019;8(2):72–79 (In Russ). doi: 10.24411/2305-3496-2019-12010Miao Z, Zhang S, Ou X, et al. Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection. J Infect Dis. 2020 Apr 27;221(10):1677–1687. doi: 10.1093/infdis/jiz633Miao Z, Zhang S, Ou X, et al. Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection. J Infect Dis. 2020 Apr 27;221(10):1677–1687. doi: 10.1093/infdis/jiz633.Chen H.Y., Shen D.T., Ji D.Z., et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis Gut. 2019. Vol. 68, № 3. P. 512–521. doi: 10.1136/gutjnl-2018-316601Chen H.Y., Shen D.T., Ji D.Z., et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis Gut. 2019. Vol. 68, № 3. P. 512–521. doi: 10.1136/gutjnl-2018-316601Vlachogiannakos J, Papatheodoridis GV. New epidemiology of hepatitis delta. Liver Int. 2020. Vol. 40, Suppl. P. 148–153. doi: 10.1111/liv.14357Vlachogiannakos J, Papatheodoridis GV. New epidemiology of hepatitis delta. Liver Int. 2020. Vol. 40, Suppl. P. 148–153. doi: 10.1111/liv.14357Слепцова С. С., Малов С. И., Савилов Е. Д. и др. Клинико-эпидемиологическая характеристика гепотоцеллюлярной карциномы в Республике Саха (Якутия) Эпидемиология и Вакцинопрофилактика. 2020;19(3):33–40.Sleptsova S.S., Malov S.I. Savilov E.D., et al. Clinical and Epidemiological Characteristics of Hepatocellular Carcinoma in the Republic of Saha (Yakutia). Epidemiology and Vaccinal Prevention. 2020;19(3):33–40 (In Russ.). doi: 10.31631/2073-30462020-19-3-33-40Romeo R., Perbellini R. Hepatitis delta virus: Making the point from virus isolation up to 2014. World J Hepatol. 2015. Vol. 7, № 22. P. 2389–2395. doi: 10.4254/wjh.v7.i22.2389.Romeo R., Perbellini R. Hepatitis delta virus: Making the point from virus isolation up to 2014. World J Hepatol. 2015. Vol. 7, № 22. P. 2389–2395. doi: 10.4254/wjh.v7.i22.2389Bissinger A.L., Fehrle C., Werner C.R., et al. Epidemiology and Genotyping of Patients with Chronic Hepatitis B: Genotype Shifting Observed in Patients from Central Europe Pol J Microbiol. 2015. Vol. 64, № 1. P. 15–21.Bissinger A.L., Fehrle C., Werner C.R., et al. Epidemiology and Genotyping of Patients with Chronic Hepatitis B: Genotype Shifting Observed in Patients from Central Europe. Pol J Microbiol. 2015. Vol. 64, № 1. P. 15–21.Семенов А. В., Останкова Ю. В., Ногойбаева К. А. и др. Особенности молекулярной эпидемиологии сочетанной инфекции ВГВ/ВГD в Кыргызстане. Инфекция и иммунитет. 2016. Т. 6, № 2. С. 141–150. doi: 10.15789/2220-7619-2016-2-141-150Semenov A.V., Ostankova Yu.V., Nogoybaeva K.A., et al. Molecular epidemiology features of HBV/ВГD co-infection in Kyrgyzstan Russian Journal of Infection and Immunity = Infektsiya i immunitet. 2016. Vol. 6, № 2. P. 141–150 (In Russ). doi: 10.15789/2220-7619-2016-2-141-150Casey J.L., Niro G.A., Engle R.E., et al. Hepatitis B virus (HBV)/ hepatitis D virus (HDV) coinfection in outbreaks of acute hepatitis in the Peruvian Amazon basin: the roles of HDV genotype III and HBV genotype FJ Infect Dis. 1996. Vol. 174, № 5. P. 920–926. doi: 10.1093/infdis/174.5.920Casey J.L., Niro G.A., Engle R.E., et al. Hepatitis B virus (ВГD) coinfection in outbreaks of acute hepatitis in the Peruvian Amazon basin: the roles of ВГD genotype F. J Infect Dis. 1996. Vol. 174, № 5. P. 920–926. doi: 10.1093/infdis/174.5.920.Su C.W., Huang Y.H., Huo T.I., et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients Gastroenterology. 2006;130(6):1625–1635. doi: 10.1053/j.gastro.2006.01.035/Su C.W., Huang Y.H., Huo T.I., et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients Gastroenterology. 2006;130(6):1625–1635. doi: 10.1053/j.gastro.2006.01.035/Ott J.J., Stevens G.A., Groeger J., et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity/ Vaccine. 2012. Vol. 30, № 12. P. 2212–2219. doi: 10.1016/j.vaccine.2011.12.116Ott J.J., Stevens G.A., Groeger J., et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity Vaccine. 2012. Vol. 30, № 12. P. 2212–2219. doi: 10.1016/j.vaccine.2011.12.116Исаева О. В., Ильченко Л. Ю., Кожанова Т. В. и др. Влияние вакцинации против гепатита В на распространенность гепатита дельта в эндемичном регионе. Инфекционные болезни: новости, мнения, обучение. 2019. Т. 8, № 2. С. 36–42. doi: 10.24411/2305-34962019-12004Isaeva O.V., Ilchenko L.Yu., Kozhanova T.V., et al. The impact of universal vaccination against hepatitis B on the prevalence of hepatitis D in endemic region Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2019. Vol. 8. № 2. P. 36–42 (In Russ). doi: 10.24411/2305-3496-2019-12004Sellier P.O., Maylin S., Brichler S., et al. Hepatitis B Virus-Hepatitis D Virus mother-to-child co-transmission: A retrospective study in a developed country. Liver Int. 2018. Vol. 38, № 4. P. 611–618. doi: 10.1111/liv.13556Sellier P.O., Maylin S., Brichler S., et al. Hepatitis B Virus-Hepatitis D Virus mother-to-child co-transmission: A retrospective study in a developed country. Liver Int. 2018. Vol. 38, № 4. P. 611–618. doi: 10.1111/liv.13556Информационный бюллетень ВОЗ. Гепатит D. Доступно на: https:www.who.int/ru/news-room/fact-sheets/detail/hepatitis-d. Ссылка активна на: 30 апреля 2020.Fact sheets WHO. Hepatitis D. Available: https:www.who.int/ru/news-room/fact-sheets/detail/hepatitis-d. Accessed: 30 Apr 2020.Сюткин В. Е., Салиенко А. А. Гепатит D. Cовременное состояние проблемы и нерешённые вопросы. Эпидемиология и инфекционные болезни. Актуальные вопросы. 2013. № 4. С. 45–49.Syutkin V.E., Salienko A.A. Hepatitis D. The present state of the problem and unsolved problems Epidemiology and infectious diseases. Current items. 2013. Vol.4. P. 45–49 (In Russ).Левитан Б. Н., Дедов А. В. Гепатит дельта – 2019. Часть I: этиология, эпидемиология, особенности течения и исходы. Эффективная фармакотерапия. 2019. Т. 15, № 18. С. 42–50. doi:10.33978/2307-3586-2019-15-18-42-50Levitan B.N., Dedov А.V. Hepatitis Delta – 2019. Part I: the Aetiology, Epidemiology, Features of the Clinical Course and Outcomes. Effective pharmacotherapy. 2019. Vol. 15, № 18. P. 42–50 (In Russ). doi: 10/33978/2307-3586-2019-15-18-42-50.Chen H.Y., Shen D.T., Ji D.Z., et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut. 2019. Vol. 68, № 3. P. 512–521. doi: 10.1136/gutjnl-2018-316601.Chen H.Y., Shen D.T., Ji D.Z., et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut. 2019. Vol. 68, № 3. P. 512–521. doi: 10.1136/gutjnl-2018-316601Scarponi C.F.O., Silva R.D.N.D., Souza Filho J.A., et al. Hepatitis Delta Prevalence in South America: A Systematic Review and Meta-Analysis. Rev Soc Bras Med Trop. 2019. Vol. 52. P. e20180289. doi: 10.1590/0037-8682-0289-2018Scarponi C.F.O., Silva R.D.N.D., Souza Filho J.A., et al. Hepatitis Delta Prevalence in South America: A Systematic Review and Meta-Analysis. Rev Soc Bras Med Trop. 2019, Vol. 52. P. e20180289. doi: 10.1590/0037-8682-0289-2018Stockdale A.J., Chaponda M., Beloukas A., et al. Prevalence of hepatitis D virus infection in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Glob Health. 2017. Vol. 5, № 11. P. e992–e1003. doi: 10.1016/S2214-109X(17)30298-XStockdale A.J., Chaponda M., Beloukas A., et al. Prevalence of hepatitis D virus infection in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Glob Health. 2017. Vol. 5, № 11. P. e992–e1003. doi: 10.1016/S2214-109X(17)30298-XGaeta G.B., Stroffolini T., Chiaramonte M., et al. Chronic hepatitis D: a vanishing Disease? An Italian multicenter study. Hepatology. 2000. Vol. 32, № 4 Pt 1. P. 824–827. doi: 10.1053/jhep.2000.17711.Gaeta G.B., Stroffolini T., Chiaramonte M., et al. Chronic hepatitis D: a vanishing Disease? An Italian multicenter study Hepatology. 2000. Vol. 32, № 4. Pt 1. P. 824–827. doi: 10.1053/jhep.2000.17711Ordieres C., Navascués C.A., González-Diéguez M.L., et al. Prevalence and epidemiology of hepatitis D among patients with chronic hepatitis B virus infection: a report from Northern Spain. Eur J Gastroenterol Hepatol. 2017. Vol. 29, № 3. P. 277–283. doi: 10.1097/MEG.0000000000000795Ordieres C., Navascués C.A., González-Diéguez M.L., et al. Prevalence and epidemiology of hepatitis D among patients with chronic hepatitis B virus infection: a report from Northern Spain. Eur J Gastroenterol Hepatol. 2017. Vol. 29, № 3. P. 277–283. doi: 10.1097/MEG.0000000000000795Değertekin H., Yalçin K., Yakut M., et al. Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta- analysis. Liver Int. 2008. Vol. 28, № 4. P. 494–498. doi: 10.1111/j.1478-3231.2008.01673.xDeğertekin H., Yalçin K., Yakut M., et al. Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. Liver Int. 2008. Vol. 28, № 4. P. 494–498. doi: 10.1111/j.1478-3231.2008.01673.xManesis E.K., Vourli G., Dalekos G., et al. Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. J Hepatol. 2013. Vol. 59, № 5. P. 949–956. doi: 10.1016/j.jhep.2013.07.005Manesis E.K., Vourli G., Dalekos G., et al. Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. J Hepatol. 2013. Vol. 59, № 5. P. 949–956. doi: 10.1016/j.jhep.2013.07.005Sagnelli E., Stroffolini T., Mele A., et al. Chronic hepatitis B in Italy: new features of an old disease-approaching the universal prevalence of hepatitis B e antigen-negative cases and the eradication of hepatitis D infection. Clin Infect Dis. 2008. Vol. 46, № 1. P. 110–113. doi: 10.1086/524074Sagnelli E., Stroffolini T., Mele A., et al. Chronic hepatitis B in Italy: new features of an old disease-approaching the universal prevalence of hepatitis B e antigen-negative cases and the eradication of hepatitis D infection. Clin Infect Dis. 2008. Vol. 46, № 1. P. 110–113. doi: 10.1086/524074Stroffolini T. The changing pattern of hepatitis B virus infection over the past three decades in Italy. Dig Liver Dis. 2005. Vol. 37, № 8. P. 622–627. doi: 10.1016/j.dld.2005.02.010Stroffolini T. The changing pattern of hepatitis B virus infection over the past three decades in Italy. Dig Liver Dis. 2005. Vol. 37, № 8. P. 622–627. doi: 10.1016/j.dld.2005.02.010Zarski J.P., Marcellin P., Leroy V., et al. Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. J Hepatol. 2006. Vol. 45, № 3. P. 355–360. doi:10.1016/j.jhep.2006.03.007Zarski J.P., Marcellin P., Leroy V., et al. Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. J Hepatol. 2006. Vol. 45, № 3. P. 355–360. doi:10.1016/j.jhep.2006.03.007Mele A., Mariano A., Tosti M.E., et al. Acute hepatitis delta virus infection in Italy: incidence and risk factors after the introduction of the universal anti-hepatitis B vaccination campaign. Clin Infect Dis. 2007. Vol. 44, № 3. P. e17–24. doi: 10.1086/510433Mele A., Mariano A., Tosti M.E., et al. Acute hepatitis delta virus infection in Italy: incidence and risk factors after the introduction of the universal anti-hepatitis B vaccination campaign. Clin Infect Dis. 2007. Vol. 44, № 3. P. e17–24. doi: 10.1086/510433Cross T.J., Rizzi P., Horner M., et al. The increasing prevalence of hepatitis delta virus (ВГD) infection in South London. J Med Virol. 2008. Vol. 80, № 2. P. 277–282. doi: 10.1002/jmv.21078Cross T.J., Rizzi P., Horner M., et al. The increasing prevalence of hepatitis delta virus (ВГD) infection in South London. J Med Virol. 2008. Vol. 80, № 2. P. 277–282. doi: 10.1002/jmv.21078Safaie P., Razeghi S., Rouster S.D., et al. Hepatitis D diagnostics:Utilization and testing in the United States. Virus Res. 2018. Vol. 250. P. 114–117. doi: 10.1016/j.virusres.2018.03.013Safaie P., Razeghi S., Rouster S.D., et al. Hepatitis D diagnostics:Utilization and testing in the United States. Virus Res. 2018. Vol. 250. P. 114–117. doi: 10.1016/j.virusres.2018.03.013.Fattovich G., Giustina G., Christensen E., et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut. Vol. 46, № 3. P. 420–426. doi: 10.1136/gut.46.3.420Fattovich G., Giustina G., Christensen E., et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep) Gut. Vol. 46, № 3. P. 420–426. doi: 10.1136/gut.46.3.420Gish R.G., Gadano A.C. Chronic hepatitis B: current epidemiology in the Americas and implications for management. J Viral Hepat. 2006. Vol. 13, № 12. P. 787–798. doi: 10.1111/j.1365-2893.2006.00787.xGish R.G., Gadano A.C. Chronic hepatitis B: current epidemiology in the Americas and implications for management. J Viral Hepat. 2006. Vol. 13, № 12. P. 787–798. doi: 10.1111/j.1365-2893.2006.00787.xSoriano V., Sherman K.E, Barreiro P. Hepatitis delta and HIV infection. AIDS. 2017. Vol. 31, № 7. P. 875–884. doi: 10.1097/QAD.0000000000001424Soriano V., Sherman K.E, Barreiro P. Hepatitis delta and HIV infection. AIDS. 2017. Vol. 31, № 7. P. 875–884. doi: 10.1097/QAD.0000000000001424Kushner T., Serper M., Kaplan D.E. Delta hepatitis within the Veterans Affairs medical system in the United States: Prevalence, risk factors, and outcomes. J Hepatol. 2015. Vol. 63, № 3. P. 586–592. doi: 10.1016/j.jhep.2015.04.025Kushner T., Serper M., Kaplan D.E. Delta hepatitis within the Veterans Affairs medical system in the United States: Prevalence, risk factors, and outcomes. J Hepatol. 2015. Vol. 63, № 3. P. 586–592. doi: 10.1016/j.jhep.2015.04.025Gish R.G., Yi D.H., Kane S., et al. Coinfection with hepatitis B and D: epidemiology, prevalence and disease in patients in Northern California. J Gastroenterol Hepatol. 2013. Vol. 28, № 9. P. 1521–1525. doi: 10.1111/jgh.12217Gish R.G., Yi D.H., Kane S., et al. Coinfection with hepatitis B and D: epidemiology, prevalence and disease in patients in Northern California. J Gastroenterol Hepatol. 2013. Vol. 28, № 9. P.1521–1525. doi: 10.1111/jgh.12217Khodjaeva M., Ibadullaeva N., Khikmatullaeva A., et al. The medical impact of hepatitis D virus infection in Uzbekistan. Liver Int. 2019. Vol. 39, № 11. P. 2077–2081. doi: 10.1111/liv.14243Khodjaeva M., Ibadullaeva N., Khikmatullaeva A., et al. The medical impact of hepatitis D virus infection in Uzbekistan Liver Int. 2019. Vol. 39, № 11. P. 2077–2081. doi: 10.1111/liv.14243.Фролов М. Ю., Рогов В. А., Саласюк А. С. и др. Клинико-экономические аспекты применения булевиртида при хроническом гепатите. Инфекционные болезни. 2020. Vol. 18, № 2. P. 104–111. doi: 10.20953/1729-9225-2020-2-104-111Frolov M.Yu., Rogov V.A., Salasyuk A.S., et al. Clinical and economic aspects of bulevirtide use in patients with chronic hepatitis D. Infekc. bolezni (Infectious diseases). 2020. Vol. 18, № 2. P. 104–111 (In Russ). doi: 10.20953/1729-9225-2020-2-104-111Mentha N., Clement S., Negro F., et al. A review on hepatitis D: From virology to new therapies. Journal of Advanced Research. 2019. Vol. 17. P. 3–15. doi: 10.1016/j.jare.2019.03.009.Mentha N., Clement S., Negro F., et al. A review on hepatitis D: From virology to new therapies. Journal of Advanced Research. 2019. Vol. 17. P. 3–15. doi: 10.1016/j.jare.2019.03.009Da B.L., Heller T., Koh C. Hepatitis D infection: from initial discovery to current investigational therapies Gastroenterol Rep (Oxt). 2019. Vol. 7, № 4. P. 231–245. doi: 10.1093/gastro/goz023Da B.L., Heller T., Koh C. Hepatitis D infection: from initial discovery to current investigational therapies. Gastroenterol Rep (Oxt). 2019. Vol. 7, № 4. P. 231–245. doi: 10.1093/gastro/goz023.Asselah T., Loureiro D., Tout I., et al. Future treatments for hepatitis delta virus infection. Liver Int. 2020. Vol. 40, № Suppl 1. P. 54–60. doi:10.1111/liv.14356Asselah T., Loureiro D., Tout I., et al. Future treatments for hepatitis delta virus infection. Liver Int. 2020. Vol. 40, № Suppl 1. P. 54–60. doi:10.1111/liv.14356Левитан Б. Н., Дедов А. В. Гепатит дельта-2019. Часть II: современное лечение и его перспективы. Эффективная фармакотерапия. 2019. Т. 15, № 28. С. 76–82. doi: 10.33978/2307-3586-2019-15-28-76-82Levitan B.N., Dedov А.V. Hepatitis Delta – 2019. Part II: Modern Treatment and Its Promise Effective pharmacotherapy. 2019. Vol. 15, № 28. С. 76–82 (In Russ). doi: 10.33978/2307-3586-2019-15-28-76-82Gilman C., Heller T., Koh C. Chronic hepatitis delta: A state-of-the-art review and new therapies. Word J Gastroenterol. 2019. Vol. 25, № 32. P. 4580–4597. doi: 10.3748/wjg.v25.i32.4580Gilman C., Heller T., Koh C. Chronic hepatitis delta: A state-of-the-art review and new therapies. Word J Gastroenterol. 2019. Vol. 25, № 32. P. 4580–4597. doi: 10.3748/wjg.v25.i32.4580Hercun J., Koh C., Heller T. Hepatitis Delta: Prevalence, Natural History, and Treatments Options. Gastroenterol Clin North Am. 2020. Vol. 49. № 2. P. 239–252. doi: 10/1016/j.gtc.2020.01.004/Hercun J., Koh C., Heller T. Hepatitis Delta: Prevalence, Natural History, and Treatments Options. Gastroenterol Clin North Am. 2020. Vol. 49. № 2. P. 239–252. doi: 10/1016/j.gtc.2020.01.004/Yurdaydin C., Abbas Z., Buti M., et al. Treating chronic hepatitis delta: The need for surrogate markers of treatments efficacy. J Hepatol. 2019. Vol. 70, № 5. P. 1008–1015. doi: 10.1016/j.jhep.2018.12.022Yurdaydin C., Abbas Z., Buti M., et al. Treating chronic hepatitis delta: The need for surrogate markers of treatments efficacy. J Hepatol. 2019. Vol. 70, № 5. P. 1008–1015. doi: 10.1016/j.jhep.2018.12.022

The authors declare that there are no conflicts of interest present.